Daxor Expands Blood Volume Analysis Technology to Major New Jersey Hospitals
Oak Ridge, TN – February 27, 2025 – Daxor Corporation (Nasdaq: DXR), a leader in blood volume measurement technology, announced today the expansion of its blood volume analysis (BVA) technology to two significant hospitals within New Jersey’s largest academic health care system. The company anticipates maintaining its accelerated sales trajectory throughout 2025 due to current market momentum and a growing pipeline of opportunities.
These two hospitals are in the process of implementing on-site BVA analyzers. This will provide their clinical teams with immediate access to accurate blood volume measurements for critical care decisions. The implementation aims to optimize fluid management, potentially reducing both hospital stays and improving outcomes for patients dealing with heart failure and other critical conditions.
“The continued expansion of our market footprint demonstrates the effectiveness of our growth strategy. The resources we have dedicated to strengthening our sales and marketing capabilities are delivering meaningful results,” said Michael Feldschuh, CEO and President of Daxor. “This adoption by a leading healthcare system reflects the growing acknowledgment that our blood volume analysis technology plays a vital role in enhancing patient care outcomes.”
Daxor Corporation logo
Daxor’s expansion into these hospitals highlights a positive commercial advancement for the company. As academic health systems often have rigorous approval processes, each new adoption can have a proportionally significant revenue impact. These systems can also drive additional adoption across their affiliated networks.
The focus on heart failure and critical care areas targets high-value clinical areas where improved fluid management can directly affect the length of patient stays and reduce readmission rates. The company’s statement about maintaining an “accelerated sales trajectory” throughout 2025 suggests this is part of a broader commercial momentum, aligning with the healthcare systems’ increasing focus on precision medicine approaches.
For investors, the potential lies in Daxor’s ability to establish a recurring revenue model, with initial analyzer placement generating follow-on revenue. Each new hospital implementation expands this revenue stream while simultaneously creating reference customers that can shorten future sales cycles. The critical question will be how quickly Daxor can achieve adoption across the U.S. and whether they can maintain sufficient working capital to support expansion. This recent advance establishes Daxor as a company to watch in the medical technology sector.
